Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HSC-CRISPR

Financiado

Transcriptional Engineering of Hematopoietic Stem Cells using CRISPR

Hematopoietic stem cells (HSCs) reside in the bone marrow where they throughout life sustain continuous blood production through a controlled balance of differentiation and self-renewal. Transplantation of HSCs from a healthy pers... ver más

31/08/2027

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

AARHUS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-02-14

ERC-2021-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

1.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FUN-HSC TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIE... 2M€ Cerrado

ATR2023-143555 Biología molecular y celular 994K€ Cerrado

SAF2016-75613-R ESPECIFICACION DE CELULA MADRE HEMATOPOYETICA Y LEUCEMICA 436K€ Cerrado

CNS2023-144846 Biología molecular y celular 200K€ Cerrado

PDC2021-120817-I00 GENERACION DE CELULAS MADRE HEMATOPOIETICAS (HSC) Y CELULAS... 133K€ Cerrado

MetEpiStem Dissecting the crosstalk between metabolism and transcriptio... 1M€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2022-02-14
Fecha Fin: 2027-08-31

Líder del proyecto

AARHUS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Hematopoietic stem cells (HSCs) reside in the bone marrow where they throughout life sustain continuous blood production through a controlled balance of differentiation and self-renewal. Transplantation of HSCs from a healthy person can replace a defective hematopoietic system of a patient thereby curing the patient for life. HSCs have found increasing therapeutic application, e.g. in hematologic malignancies and hematopoietic genetic disorders. This applies not only to the allogeneic transplantation setting but also to the autologous setting where advances in genetic engineering technologies have enabled autologous gene therapies. However, major challenges remain in both settings pertaining to the scarcity of HSCs, as well as the cells being partially refractory to precise gene correction. In this research proposal, I will address these challenges by leveraging the unique power of repurposed CRISPR/Cas systems for precise transcriptional manipulation of HSCs. In these systems, the normal DNA-cleaving ability of the Cas9 enzyme is disabled (dCas9) while transcriptional activators or inhibitors are fused to dCas9. By targeting the dCas9-effector proteins to transcriptional start site regions by sgRNA programming, gene transcription can be activated (CRISPRa) or inhibited (CRISPRi). Complex transcriptional engineering is readily achieved using multiple sgRNAs and orthogonal CRISPR systems for simultaneous CRISPRa and CRISPRi. I will apply these technologies to investigate and enhance therapeutically relevant HSC pathways, namely homologous recombination for precise gene editing, self-renewal, and bone marrow homing. These biological phenomena have previously been studied with techniques that do not have the same elegant properties and therapeutic relevance as CRISPRa/i. With this new state-of-the-art method for precisely controlling gene expression, I will study and manipulate genetic pathways to overcome long-standing challenges in HSC therapies.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores